课题基金 / 基金详情

PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS

PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
CTCL <3 既往治疗中两剂 DA389IL-2 的 III 期随机试验
批准号：
6275788
负责人：
BRIAN JEGASOTHY
金额：
$1.91万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6275788
关键词：
clinical research drug administration rate /duration human subject human therapy evaluation immunoconjugates interleukin 2 mycosis fungoides lymphoma neoplasm /cancer immunotherapy

项目摘要

项目成果

BRIAN JEGASOTHY的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this clinical study is to demonstrate the efficacy of two dose levels of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) patients, as assessed by a)frequency & duration of complete response, clinical complete response, & partial responses; b)changes in CTCL symptoms & functional status and c) to further evaluate the safety and tolerability of DAB389IL-2 for these doses and schedules of treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS
MULTICENTER PHASE 3 TRIAL OF DAB3891L-2 IN CTCL PATIENTS IN STAGE IA-IVA DISEASE
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS